SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
18.7 EUR
+0.2 (+1.08%)
1SXP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 19 industry peers in the Life Sciences Tools & Services industry. 1SXP has an excellent profitability rating, but there are some minor concerns on its financial health. 1SXP is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
In the past year 1SXP had a positive cash flow from operations.
Each year in the past 5 years 1SXP has been profitable.
Each year in the past 5 years 1SXP had a positive operating cash flow.
1.2 Ratios
The Return On Assets of 1SXP (9.62%) is better than 94.74% of its industry peers.
The Return On Equity of 1SXP (17.03%) is better than 89.47% of its industry peers.
1SXP's Return On Invested Capital of 13.86% is amongst the best of the industry. 1SXP outperforms 94.74% of its industry peers.
1SXP had an Average Return On Invested Capital over the past 3 years of 15.67%. This is significantly above the industry average of 7.47%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.62% | ||
| ROE | 17.03% | ||
| ROIC | 13.86% |
ROA(3y)11.07%
ROA(5y)11.97%
ROE(3y)19.57%
ROE(5y)21.49%
ROIC(3y)15.67%
ROIC(5y)17.02%
1.3 Margins
1SXP has a better Profit Margin (15.07%) than 89.47% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
1SXP has a better Operating Margin (19.41%) than 84.21% of its industry peers.
In the last couple of years the Operating Margin of 1SXP has grown nicely.
1SXP has a worse Gross Margin (33.73%) than 63.16% of its industry peers.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.41% | ||
| PM (TTM) | 15.07% | ||
| GM | 33.73% |
OM growth 3Y4.06%
OM growth 5YN/A
PM growth 3Y0.29%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1SXP is creating value.
Compared to 1 year ago, 1SXP has more shares outstanding
Compared to 1 year ago, 1SXP has about the same debt to assets ratio.
2.2 Solvency
1SXP has a debt to FCF ratio of 1.69. This is a very positive value and a sign of high solvency as it would only need 1.69 years to pay back of all of its debts.
1SXP's Debt to FCF ratio of 1.69 is amongst the best of the industry. 1SXP outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.09, 1SXP belongs to the best of the industry, outperforming 94.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | N/A |
ROIC/WACC1.69
WACC8.22%
2.3 Liquidity
A Current Ratio of 1.57 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP's Current ratio of 1.57 is fine compared to the rest of the industry. 1SXP outperforms 78.95% of its industry peers.
1SXP has a Quick Ratio of 1.16. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP has a Quick ratio of 1.16. This is in the better half of the industry: 1SXP outperforms 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.00%.
Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.90% on average per year.
1SXP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.86%.
1SXP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.84% yearly.
EPS 1Y (TTM)-3%
EPS 3Y13.9%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
1SXP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.13% yearly.
The Revenue is expected to grow by 8.14% on average over the next years. This is quite good.
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.13%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y8.14%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.28, which indicates a rather expensive current valuation of 1SXP.
78.95% of the companies in the same industry are more expensive than 1SXP, based on the Price/Earnings ratio.
1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 25.65, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 15.98 indicates a correct valuation of 1SXP.
Based on the Price/Forward Earnings ratio, 1SXP is valued a bit cheaper than 78.95% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.45. 1SXP is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.28 | ||
| Fwd PE | 15.98 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1SXP is valued a bit cheaper than 78.95% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.22 | ||
| EV/EBITDA | 10.66 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)5.94
PEG (5Y)N/A
EPS Next 2Y8.71%
EPS Next 3Y10.5%
5. Dividend
5.1 Amount
1SXP has a yearly dividend return of 0.87%, which is pretty low.
1SXP's Dividend Yield is a higher than the industry average which is at 0.73.
Compared to an average S&P500 Dividend Yield of 2.41, 1SXP's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.87% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
1SXP pays out 16.33% of its income as dividend. This is a sustainable payout ratio.
DP16.33%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
FRA:1SXP (11/25/2025, 10:21:00 AM)
18.7
+0.2 (+1.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.82B
Revenue(TTM)975.68M
Net Income(TTM)147.00M
Analysts78.95
Price Target29.58 (58.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.87% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.33%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.82%
PT rev (3m)-1.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.65%
EPS NY rev (3m)-1.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)-0.3%
Revenue NY rev (3m)-1.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.28 | ||
| Fwd PE | 15.98 | ||
| P/S | 2.89 | ||
| P/FCF | 55.22 | ||
| P/OCF | 13.81 | ||
| P/B | 3.26 | ||
| P/tB | 3.38 | ||
| EV/EBITDA | 10.66 |
EPS(TTM)0.97
EY5.19%
EPS(NY)1.17
Fwd EY6.26%
FCF(TTM)0.34
FCFY1.81%
OCF(TTM)1.35
OCFY7.24%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)5.94
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.62% | ||
| ROE | 17.03% | ||
| ROCE | 16.98% | ||
| ROIC | 13.86% | ||
| ROICexc | 14.4% | ||
| ROICexgc | 14.81% | ||
| OM | 19.41% | ||
| PM (TTM) | 15.07% | ||
| GM | 33.73% | ||
| FCFM | 5.23% |
ROA(3y)11.07%
ROA(5y)11.97%
ROE(3y)19.57%
ROE(5y)21.49%
ROIC(3y)15.67%
ROIC(5y)17.02%
ROICexc(3y)16.17%
ROICexc(5y)17.75%
ROICexgc(3y)16.77%
ROICexgc(5y)18.76%
ROCE(3y)19.22%
ROCE(5y)20.88%
ROICexgc growth 3Y-8.55%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.4%
ROICexc growth 5YN/A
OM growth 3Y4.06%
OM growth 5YN/A
PM growth 3Y0.29%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 204% | ||
| Cap/Sales | 15.68% | ||
| Interest Coverage | 11.79 | ||
| Cash Conversion | 77.17% | ||
| Profit Quality | 34.69% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | N/A |
F-Score5
WACC8.22%
ROIC/WACC1.69
Cap/Depr(3y)291.66%
Cap/Depr(5y)279.8%
Cap/Sales(3y)17.76%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.94%
Profit Quality(5y)27.76%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y13.9%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.13%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y8.14%
EBIT growth 1Y11.76%
EBIT growth 3Y18.46%
EBIT growth 5YN/A
EBIT Next Year46.93%
EBIT Next 3Y24.15%
EBIT Next 5Y18.78%
FCF growth 1Y-26.72%
FCF growth 3Y33.53%
FCF growth 5YN/A
OCF growth 1Y-5.2%
OCF growth 3Y19.39%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 19.28 and the Price/Book (PB) ratio is 3.26.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 3 / 10 and the dividend payout ratio is 16.33%.